1. BEGIN Files 458, 459 to retrieve the most current pharmaceutical news.

? BEGIN 458,459
SYSTEM:OS  - DIALOG OneSearch
  File 458:Daily Essentials 2010/Feb 25 
         (c) 2010 Prous Science
  File 459:Daily Essentials (Archival) 1996-2010/Feb W2
         (c) 2010 Prous Science

      Set  Items  Description
      ---  -----  -----------

2. SELECT the company name and a date range (PY=).

? S ASTRAZENECA/CO AND PY=2009:2010
            2093  ASTRAZENECA/CO
            7282  PY=2009 : PY=2010

3. The Therapeutic Class field (TC=, /TC) contains specialized indexing regarding company news or company profiles & pipeline.  SELECT TC=COMPANY PROFILES & PIPELINES.

? S TC=COMPANY PROFILES & PIPELINES
      S2    3354  TC=COMPANY PROFILES & PIPELINES

4. Combine Sets 1 and 2.

? S S1 AND S2
             185  S1
            3354  S2
      S3      12  S1 AND S2

5. TYPE S3 using Format 6 to see the first few records in a free format (titles, publication date).

Note:  Some records have been omitted from this display.

AstraZeneca was mentioned in the Bristol-Myers Squibb report, and so it was indexed on the company name field.

? T S3/6/1-3
3/6/1 (Item 1 from file: 458) 
DIALOG(R)File 458: Daily Essentials
(c) 2010 Prous Science. All rights reserved.

00101579 

ASTRAZENECA REPORTS RESULTS FROM Q4 2009 AND THE YEAR'S R&D HIGHLIGHTS

February 23, 2010 (20100223) 

3/6/2 (Item 2 from file: 458) 
DIALOG(R)File 458: Daily Essentials
(c) 2010 Prous Science. All rights reserved.

00101431 

BRISTOL-MYERS SQUIBB REPORTS RESULTS FROM FOURTH QUARTER 2009, ENDED DECEMBER 31

February 16, 2010 (20100216) 

3/6/3 (Item 1 from file: 459) 
DIALOG(R)File 459: Daily Essentials (Archival)
(c) 2010 Prous Science. All rights reserved.

00099993

BRISTOL-MYERS SQUIBB REPORTS RESULTS FROM THIRD QUARTER OF 2009

November 24, 2009 (20091124)

6. TYPE the record(s) you want using Format 9 to see the complete record.

Drugs in the pipeline

Licensing agreement discussed

? TYPE S3/9/1
3/9/1 (Item 1 from file: 458) 
DIALOG(R)File 458: Daily Essentials
(c) 2010 Prous Science. All rights reserved.

00101579 

ASTRAZENECA REPORTS RESULTS FROM Q4 2009 AND THE YEAR'S R&D HIGHLIGHTS

Daily Essentials 
February 23, 2010 (20100223) 
Document Type: Quarterly/Semi-Annual/Annual Reports 
Language: English 
Record Type: Fulltext 

AstraZeneca has reported results from the fourth quarter of 2009, as well as the year's R&D highlights and a pipeline update.

  The AstraZeneca pipeline now includes 146 projects, including 103 projects in the clinical phase of development. There are 11 new molecular entity projects currently in late-stage development, either in phase III or under regulatory review.

  Several products are currently awaiting registration: Brilinta(TM) (ticagrelor), an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome, is under review in the U.S. and Europe; Vimovo(TM) (naproxen/esomeprazole magnesium), a product for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing ulcers associated with nonsteroidal

...

  In September, AstraZeneca and Nektar Therapeutics entered into an exclusive worldwide license agreement for two drug development programs: NKTR-118 (PEG-naloxol), a late-stage investigational product being evaluated for opioid-induced constipation and NKTR-119, an early-stage program that is intended to deliver products for the treatment of pain without constipation side effects. Under the terms of the agreement, AstraZeneca will assume responsibility for the continued development of both compounds, including the initiation of late-stage clinical activities for NKTR-118. AstraZeneca expects completion of the design of the phase III program in the near future and anticipates filing the drug with regulators in 2013.

  In November, AstraZeneca presented results for ticagrelor (Brilinta(TM)) from the PLATO subanalysis in patients with ST segment elevation myocardial infarction. The subanalysis showed that, compared to clopidogrel, treatment

  ...

  Finally, the company discontinued a number of projects during the fourth quarter. In cardiovascular disease, AZD-1305 was discontinued in arrhythmia. In neuroscience, AstraZeneca will discontinue AZD-5904 for multiple sclerosis, AZD-6088 for chronic neuropathic pain, AZD-1386 for chronic neuropathic pain, AZD-7325 for anxiety and AZD-4694 for Alzheimer's disease as a positron emission tomography diagnostic. In oncology and infection, the company discontinued AZD-9639 for treatment of respiratory syncytial virus infection, its cytomegalovirus vaccine for cytomegalovirus infection and Zactima(R) for non-small cell lung cancer. In respiratory and inflammation, Symbicort(R) pMDI (budesonide/formoterol fumarate) was discontinued in the E.U. for asthma and chronic obstructive pulmonary disease (AstraZeneca News Release).

  ...